Spruce Biosciences
SPRB
3 hedge funds and large institutions have $147K invested in Spruce Biosciences in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 28 closing their positions.
90% less funds holding
Funds holding: 31 → 3 (-28)
95% less capital invested
Capital invested by funds: $3.03M → $147K (-$2.88M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 28
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carlyle Group
Washington,
District of Columbia
|
-$840K |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$757K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$245K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$117K |
| 5 |
Renaissance Technologies
New York
|
-$111K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| – | -$2.15K | -99 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$1.36K | -63 | Closed |
|
28
Group One Trading
Chicago,
Illinois
| – | -$334 | -15 | Closed |
|
29
Bank of America
Charlotte,
North Carolina
| – | -$68 | -3 | Closed |
|
30
BNP Paribas Financial Markets
Paris,
France
| – | -$52 | -2 | Closed |
|
31
JP Morgan Chase
New York
| – | -$19 | -1 | Closed |
|
SPRB Hedge Fund Activity: Q2 2025 in Review
3 of the 7,604 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q2 2025, worth a combined $147K — down 95% from $3.03M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of SPRB and 0 opened new positions — a net loss of 28 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Carlyle Group, exiting entirely with an estimated $840K sold.
- 3 institutional investors held Spruce Biosciences (SPRB) as of Q2 2025, down from 31 in Q1 2025.
- Funds reported $147K of Spruce Biosciences stock for Q2 2025, down 95% quarter-over-quarter.
- 0 funds opened new Spruce Biosciences positions in Q2 2025 and 28 closed out, a net change of -28 holders.
- The largest Spruce Biosciences seller in Q2 2025 was Carlyle Group, an estimated $840K sold.
Based on aggregated 13F filings for Q2 2025.